BiotechTube
Home/Myosin Therapeutics/Theodore Kamenecka
TK

Theodore Kamenecka

Chief Scientific Officer

Myosin Therapeutics

Therapeutic Areas

OncologyNeuroscienceMusculoskeletal

Myosin Therapeutics Pipeline

DrugIndicationPhase
MT-125Glioblastoma (GBM), MGMT unmethylatedPhase 1/2
MT-228Oncology (likely PDAC)Preclinical
MT-110Substance Use Disorder (SUD)Preclinical
MT-134MusculoskeletalPreclinical

Leadership Team at Myosin Therapeutics

CA
Courtney A. Miller
Chief Executive Officer
KS
Karen Smith
Chief Medical Officer
PR
Patrick R. Griffin
Chief Scientific Officer
View full Myosin Therapeutics profile